Payment overview · 2025
General Payments
$154.07
8 reported records · 7 companies
Healthcare provider profile · identity verified
Gerard K Williams, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAFAYETTE, LA · NPI 1295728749
Verified facts
What the public records show
CMS Open Payments records show Gerard K Williams, MD received $154.07 in general payments during 2025 across 8 reported records.
Exact Sciences Corporation accounted for 25.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Linzess by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $38.45 | 25.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $27.19 | 17.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.65 | 12.8% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $19.26 | 12.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.58 | 12.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.93 | 11.0% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $14.01 | 9.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $154.07 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $38.45 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $27.19 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.58 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.93 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $14.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
121 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 629 | 102 |
| Atorvastatin Calcium | Atorvastatin Calcium | 567 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 410 | 54 |
| Gabapentin | Gabapentin | 357 | 59 |
| Metformin Hcl | Metformin Hcl | 328 | 55 |
| Furosemide | Furosemide | 327 | 47 |
| Eliquis | Apixaban | 291 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 278 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 268 | 39 |
| Trazodone Hcl | Trazodone Hcl | 265 | 44 |
| Lisinopril | Lisinopril | 229 | 35 |
| Potassium Chloride | Potassium Chloride | 222 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 219 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 215 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 212 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 201 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 201 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 192 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 187 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 177 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 175 | 30 |
| Meloxicam | Meloxicam | 169 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 163 | 26 |
| Tramadol Hcl | Tramadol Hcl | 160 | 32 |
| Omeprazole | Omeprazole | 156 | 26 |
| Famotidine | Famotidine | 154 | 25 |
| Lorazepam | Lorazepam | 154 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 150 | 36 |
| Levetiracetam | Levetiracetam | 148 | 17 |
| Sertraline Hcl | Sertraline Hcl | 146 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 143 | 17 |
| Donepezil Hcl | Donepezil Hcl | 140 | 21 |
| Alendronate Sodium | Alendronate Sodium | 134 | 21 |
| Montelukast Sodium | Montelukast Sodium | 130 | 28 |
| Losartan Potassium | Losartan Potassium | 127 | 21 |
| Memantine Hcl | Memantine Hcl | 125 | 17 |
| Risperidone | Risperidone | 125 | 15 |
| Carvedilol | Carvedilol | 124 | 25 |
| Linzess | Linaclotide | 121 | 11 |
| Mirtazapine | Mirtazapine | 119 | 14 |
| Finasteride | Finasteride | 116 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 113 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 113 | 22 |
| Simvastatin | Simvastatin | 102 | 20 |
| Buspirone Hcl | Buspirone Hcl | 99 | 15 |
| Xarelto | Rivaroxaban | 98 | suppressed |
| Januvia | Sitagliptin Phosphate | 83 | suppressed |
| Glipizide | Glipizide | 80 | 16 |
| Glipizide Er | Glipizide | 76 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 75 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 73 | 12 |
| Ezetimibe | Ezetimibe | 68 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 67 | suppressed |
| Latanoprost | Latanoprost | 63 | suppressed |
| Spironolactone | Spironolactone | 63 | suppressed |
| Tradjenta | Linagliptin | 63 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 61 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 12 |
| Baclofen | Baclofen | 60 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 59 | suppressed |
| Topiramate | Topiramate | 59 | suppressed |
| Ibuprofen | Ibuprofen | 57 | 12 |
| Rexulti | Brexpiprazole | 55 | suppressed |
| Allopurinol | Allopurinol | 54 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 54 | suppressed |
| Prednisone | Prednisone | 54 | 28 |
| Fenofibrate | Fenofibrate Nanocrystallized | 53 | suppressed |
| Ozempic | Semaglutide | 49 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 48 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 48 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | suppressed |
| Levofloxacin | Levofloxacin | 45 | 33 |
| Jardiance | Empagliflozin | 44 | suppressed |
| Scopolamine | Scopolamine | 44 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 14 |
| Cilostazol | Cilostazol | 43 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | suppressed |
| Aripiprazole | Aripiprazole | 41 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 41 | 11 |
| Nystatin | Nystatin | 41 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Cyclosporine | Cyclosporine | 39 | suppressed |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 28 |
| Torsemide | Torsemide | 39 | suppressed |
| Alprazolam | Alprazolam | 36 | suppressed |
| Carbamazepine | Carbamazepine | 36 | suppressed |
| Lamotrigine | Lamotrigine | 36 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 36 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | suppressed |
| Primidone | Primidone | 35 | suppressed |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Lactulose | Lactulose | 34 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Calcitriol | Calcitriol | 33 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 33 | suppressed |
| Ingrezza | Valbenazine Tosylate | 33 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 32 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 17 |
| Valsartan | Valsartan | 32 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 22 |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | 14 |
| Oxcarbazepine | Oxcarbazepine | 31 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 31 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 30 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Phenobarbital | Phenobarbital | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Colchicine | Colchicine | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Multaq | Dronedarone Hcl | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 21 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Rivastigmine | Rivastigmine | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Trimethoprim | Trimethoprim | 22 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 19 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 19 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 15 |
| Pregabalin | Pregabalin | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 15 | suppressed |
| Levemir | Insulin Detemir | 15 | suppressed |
| Perphenazine | Perphenazine | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $154.07 · 8 records | Exact Sciences Corporation | Azstarys, Cologuard Collection Kit, IBSRELA, JARDIANCE, MOUNJARO, REXULTI, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error